Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial

Alexander C. Ford(University of Leeds), Damien Hindmarch, Sonia Newman(University of Southampton), Matthew J Ridd(University of Bristol), Ruth B. Thornton(University of Southampton), Alexandra Wright‐Hughes(University of Leeds), Delia Muir(University of Leeds), Jake Emmerson, Hazel Everitt(University of Southampton), Amanda Farrin, Elspeth Guthrie(University of Leeds), Sarah Alderson(University of Leeds), Suzanne Hartley(University of Leeds), Robbie Foy, Felicity L. Bishop(University of Southampton), Sarah Brown(University of Leeds), Amy L Herbert(University of Bristol), Emma Teasdale(University of Southampton), Florence Day(University of Nottingham), Thomas A. Smith(Swiss Tropical and Public Health Institute), Heather Cook(University of Leeds), Daniel Howdon(University of Leeds), Matthew Chaddock, Maggie Barratt, Pei-Loo Ow(University of Leeds), Aaron Dowse, Jill Durnell, Christopher A. Taylor(Centers for Disease Control and Prevention), Richard Brindle, Gina Bianco(University of Leeds), Alasdair Fellows(University of Leeds), Deborah Cooper(University of Leeds), Catherine Fernandez(University of Leeds)
The Lancet
October 16, 2023
Cited by 138


Related Papers